Loading the company…
Loading the company…
㈜다원케미칼
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 1969. Industry: Bio & Pharma. Revenue for 2025 was ₩44.8bn. It has 51 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2013-05-28 · latest registration 2016-11-10 · newest first
쑥 추출물을 포함하는 것을 특징으로 하는 자돈의 장염 예방 또는 치료용 조성물이 개시된다. 본 조성물은 자돈의 면역증강작용을 통하여 장염의 예방 또는 치료효과를 발현한다.
본 발명은 면역 및 항바이러스 활성이 우수한 유산균 균주 및 이의 발효 방법에 관한 것으로, 보다 상세하게는 면역 및 항바이러스 활성이 우수한 락토바실러스 플란타룸(Lactobacillus plantarum) GB-LP1(KCCM 11258P) 유산균 균주, 상기 유산균 균주를 혐기 조건에서 발효하는 유산균 균주의 발효방법, 및 이로부터 획득한 유산균 발효물을 포함하는 사료에 관한 것이다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 37.0 | 44.8 |
| Cost of sales | 29.8 | 36.9 |
| Gross profit (loss) | 7.3 | 7.9 |
| Selling, general and administrative expenses | 5.5 | 5.9 |
| Operating income (loss) | 1.7 | 2.0 |
| Non-operating income | 0.7 | 0.8 |
| Other gains | 0.0 | 0.1 |
| Finance income | 0.6 | 0.7 |
| Non-operating expenses | 0.8 | 0.6 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.8 | 0.6 |
| Profit (loss) before tax | 1.6 | 2.3 |
| Income tax expense | 0.3 | 0.4 |
| Net income (loss) | 1.3 | 1.9 |
Revenue ₩44.8bn, up 20.9% YoY.
Operating margin 4.6% (prior 4.7%).
Net income ₩1.9bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06